Short answer: investors do not just look at your FDA pathway. They look at how realistic your pathway assumptions are. If your regulatory strategy sounds optimistic, your valuation will be discounted. In medical device investing, the chosen pathway—510(k), De Novo, or PMA—is more than a regulatory decision. It is a signal of timeline stability, capital […]
Blog
Predicate Devices: What Founders Get Wrong
Short answer: marketing similarity is not the same as regulatory substantial equivalence.
Many founders believe that if their device “looks like” something already on the market, they can file a 510(k). That assumption is one of the most common regulatory mistakes in medical device development.
The 100-Year Mirage: Why Modern Longevity is a Childhood Survival Story
We often hear that modern science has “doubled” the human lifespan. We look at the statistics from 1840—where life expectancy was a mere 40 years—and compare them to our 80-year average today, assuming we’ve fundamentally reengineered human biology.
But the data tells a different, more sobering story.
Why “We’ll Try 510(k)” Is a Red Flag
Short answer: when a team says, “We’ll try 510(k),” it usually means the regulatory strategy is not fully developed.
A 510(k) is not something you “try.” It is something you qualify for.
Under the framework of the U.S. Food and Drug Administration, the 510(k) pathway depends on a very specific standard: substantial equivalence to a legally marketed predicate device.
If that logic is not solid, the pathway collapses.
What Is the Difference Between 510(k), De Novo, and PMA—Really?
Short answer: the real difference between 510(k), De Novo, and PMA is not speed. It is risk tolerance.
Each pathway reflects how much uncertainty the U.S. Food and Drug Administration is willing to accept—and how much evidence they require to reduce that uncertainty.
FDA Pathways as Portfolio Risk Indicators
Short answer: an FDA regulatory pathway is not just a compliance decision. It is a portfolio risk signal. For investors, the difference between 510(k), De Novo, and PMA is not technical—it’s financial. Each pathway signals a different level of timeline risk, capital intensity, and probability of return. Understanding that signal changes how smart investors allocate […]
The Hidden Cost of Choosing the Wrong FDA Pathway
Direct answer: choosing the wrong FDA pathway does not just delay your launch. It can add millions in cost, years in delay, and materially reduce company valuation.
Most pathway mistakes happen early—when teams assume a 510(k) is viable without fully pressure-testing risk, intended use, or technological differences.
Why Pathway Mistakes Surface During Investor Diligence
Short answer: incorrect FDA pathway assumptions don’t usually fail at the beginning. They fail when investors start asking hard questions.
Early on, optimism hides regulatory gaps. During investor diligence, those gaps get exposed.
That’s because regulatory pathway decisions—510(k), De Novo, or PMA—are not just technical. They define your timeline, capital needs, and exit strategy.
How Device Classification Controls Timelines
Straight answer: device classification controls how much evidence you must generate—and that controls how fast (or slow) you reach market.
If you don’t understand your classification early, your timeline is not a plan. It’s a guess.
Under the framework of the U.S. Food and Drug Administration, medical devices are placed into three risk-based classes: Class I, Class II, and Class III. The higher the risk, the heavier the evidence burden—and the longer the timeline.